High Triglycerides News and Research

RSS
First study to examine how changes in fitness and fatness affect heart health

First study to examine how changes in fitness and fatness affect heart health

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

Link between sugar-sweetened beverages and increased cardiovascular risk in women

Link between sugar-sweetened beverages and increased cardiovascular risk in women

Spherix closes private placement transaction

Spherix closes private placement transaction

New drug could combat cardiovascular disease

New drug could combat cardiovascular disease

EAS/ESC develops new dyslipidaemias guidelines

EAS/ESC develops new dyslipidaemias guidelines

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Surge of generics will trigger drop in drug prices

Surge of generics will trigger drop in drug prices

EAS, ESC develop new European guidelines to manage dyslipidaemias

EAS, ESC develop new European guidelines to manage dyslipidaemias

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Most Americans unaware of recommended alcohol limits and risks of sea salt

Most Americans unaware of recommended alcohol limits and risks of sea salt

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Refined carbohydrates create an ill and obese population

Refined carbohydrates create an ill and obese population

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera to fund Epanova Phase 3 development with $33.9 million in Series B funding

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Lifestyle therapy program may help manage cardiovascular risk factors

Lifestyle therapy program may help manage cardiovascular risk factors

Positive PK study results from ECLIPSE trial against cardiovascular disease

Positive PK study results from ECLIPSE trial against cardiovascular disease

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy